IP Library Granted Patent US 10,471,212
Granted Patent B2
US 10,471,212 · App. 15/425,082 · Granted Nov 12, 2019

Silicone free drug delivery devices

Inventors: Edgar G. Ashmead (Lincoln University, PA); Edward C. Gunzel (Oxford, PA); Michael P. Moritz (Media, PA)
Assignee: W. L. Gore & Associates, Inc.
A61M5/31513A61K35/12A61K38/4846A61M5/3202A61M2005/3118A61M2005/3131A61M2205/0238A61M2207/00Y10T156/1043Y10T428/1321Y10T428/1352Y10T428/1359Y10T428/1376Y10T428/24992Y10T428/3154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,471,212
App. No.
15/425,082
Granted
Nov 12, 2019
Kind
B2
Abstract

A pre-filled syringe having containing therein at least one therapeutic is provided. The syringe contains a silicone free barrel and an elastomeric syringe stopper that is covered with an expanded polytetrafluoroethylene barrier layer. The presence of a barrier layer that is at least partially porous on the outside of the syringe stopper improves the seal between the stopper and syringe barrel and minimizes the sliding force. In some embodiments, the barrel is formed of a glass material such as a borosilicate glass, that is free of silicone or other lubricants.

Claims (30)

1. A pre-filled syringe comprising:

a silicone free syringe barrel containing at least one therapeutic; and

a syringe stopper comprising:

(a) an elastomeric material,

(b) a composite layer having a first side consisting of an expanded polytetrafluoroethylene film and a second side comprising a thermoplastic fluoropolymer, and

(c) a densified expanded polytetrafluoroethylene film where the composite layer is adjacent to the elastomeric material and the densified expanded fluoropolymer film is adjacent to the second side of the composite layer.

2. The pre-filled syringe of claim 1 , wherein said therapeutic comprises at least one bioactive selected from coagulation factors, cytokines, epigenetic protein families, growth factors, hormones, peptides, signal transduction molecules, vaccines, and combinations thereof.

3. The pre-filled syringe of claim 1 , wherein said therapeutic comprises mutations of a bioactive selected from coagulation factors, cytokines, epigenetic protein families, growth factors, hormones, peptides, signal transduction molecules, vaccines, and combinations thereof.

4. The pre-filled syringe of claim 1 , wherein said therapeutic comprises at least one bioactive selected from protein kinases, esterases, phosphatases, ion channels, proteases, structural proteins, membrane transport proteins, nuclear hormone receptors, and mutations and combinations thereof.

5. The pre-filled syringe of claim 1 , wherein said therapeutic comprises at least one bioactive selected from antibodies, antisense, RNA interference, target receptors, and combinations thereof.

6. The pre-filled syringe of claim 1 , wherein said therapeutic comprises at least one bioactive selected from primary and embryonic stem cells.

7. The pre-filled syringe of claim 1 , wherein the therapeutic is factor VII.

8. The pre-filled syringe of claim 1 used for treatment of ocular disease.

9. A pre-filled syringe comprising:

a silicone free syringe barrel containing at least one therapeutic; and

an elastomeric stopper comprising:

an elastomeric material;

a composite layer having a first side consisting of an expanded polytetrafluoroethylene film and a second side comprising a thermoplastic fluoropolymer; and

a fluoropolymer film,

wherein the first side of the composite layer is bonded to the elastomeric material and the second side is bonded to the fluoropolymer film.

10. The pre-filled syringe of claim 9 , wherein said therapeutic comprises at least one bioactive selected from coagulation factors, cytokines, epigenetic protein families, growth factors, hormones, peptides, signal transduction molecules, vaccines and combinations thereof.

11. The pre-filled syringe of claim 9 , wherein said therapeutic comprises at least one bioactive selected from antibodies, antisense, RNA interference, target receptors, and combinations thereof.

12. The pre-filled syringe of claim 9 , wherein said therapeutic comprises mutations of a bioactive selected from coagulation factors, cytokines, epigenetic protein families, growth factors, hormones, peptides signal transduction molecules, vaccines, and combinations thereof.

13. The pre-filled syringe of claim 9 , wherein said therapeutic comprises at least one bioactive selected from protein kinases, esterases, phosphatases, ion channels, proteases, structural proteins, membrane transport proteins, nuclear hormone receptors, and mutations and combinations thereof.

14. The pre-filled syringe of claim 9 , wherein said therapeutic comprises at least one bioactive selected from antibodies, antisense, RNA interference, target receptors, and combinations thereof.

15. The pre-filled syringe of claim 9 , wherein said therapeutic comprises at least one bioactive selected from primary and embryonic stem cells.

16. The pre-filled syringe of claim 9 , wherein the therapeutic is factor VII.

17. The pre-filled syringe of claim 9 used for treatment of ocular disease.

18. The pre-filled syringe of claim 1 , wherein the syringe stopper has a slide force less than 15 N on said barrel.

19. The pre-filled syringe of claim 9 , wherein the syringe stopper has a slide force less than 15 N on said barrel.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2017
From: ASHMEAD, EDGAR G.; GUNZEL, EDWARD C.
To: W. L. GORE & ASSOCIATES, INC.
Reel/Frame 043904/0644 →
Continuity (4)
Continuation In Part 13117573 · May 27, 2011
Continuation In Part 12915850 · Oct 29, 2010
Provisional Application 61256156 · Oct 29, 2009
Related Publication 20170173267A1 · Jun 22, 2017
Cited By (5)
US 1,116,103 US 1,120,314 US 12,274,865 US 12,649,031 US 12,691,227